Bruker (NASDAQ: BRKR) today announced the official opening of a new
Preclinical Imaging Center of Excellence for the Americas in Billerica,
Massachusetts. The facility offers advanced development, demonstration
and support facilities for Bruker’s industry-leading portfolio of
preclinical imaging instrumentation and multimodal platforms.
Bruker’s new preclinical imaging Center of Excellence in Billerica, Massachusetts (Photo: Business Wire)
In showcasing both the individual imaging technologies and the benefits
gained from combining multimodal experiments, the Center will play a key
role in promoting the successful application of complementary imaging
information in preclinical research in oncology, cardiology,
inflammation, musculoskeletal imaging and the neurosciences.
Bruker customers will participate in an opening symposium for the new
center today, with many New England research institutions and
pharmaceutical companies present. Speakers from Bruker’s management will
be joined by Srinivasan Mukundan Jr., MD/PhD, Chief of Neuroradiology at
Brigham and Women’s Hospital in Boston, who will highlight the
importance of cutting-edge technology innovation for preclinical imaging
research, while adding translational perspectives from the clinic. The
event will allow members of the preclinical imaging community to
interact with the Bruker imaging instruments, all running live in the
lab.
“I am really excited to see the establishment of a full-featured,
preclinical imaging laboratory in the Boston area,” said Frederic Fahey,
DSc, Director of Nuclear Medicine Physics at Boston Children's Hospital.
“We look forward to the development of many new collaborations and
innovations as a result of this endeavor by Bruker.”
The new Bruker Center of Excellence represents a significant global
infrastructure expansion for all technical R&D, support and
demonstration centers worldwide. Located at Bruker’s headquarters in
Billerica, the new center features dedicated lab space for showcasing
the latest preclinical imaging technologies and multimodal platforms,
together with tissue culture and in vivo subject handling
capabilities.
Utilizing Bruker’s preclinical instruments for demonstration and
applications development in a single site, visiting customers and Bruker
scientists will be able to offer unparalleled levels of support and
training, and provide access to new combinations of imaging modalities.
Multiple modalities such as optical imaging and X-ray, or PET and MRI
enable researchers to acquire complementary image information, e.g. on
morphology and function, which is vital in the further development of
medical sciences and translational research.
“The Bruker Preclinical Imaging division is committed to providing
cutting-edge tools and we are excited about our ability to combine
multiple modalities in one lab to help facilitate new insights for the
imaging research community,” commented Dr. Wulf Jung, President of
Bruker BioSpin’s Preclinical Imaging division.
The new PCI Center provides access to MRI instruments including a 7
Tesla BioSpec® MRI system with a
unique MRI CryoProbe™, and an ICON™ compact,
benchtop MRI system. Micro computed X-ray tomography (µCT) is covered by
several models, including the in vivo Skyscan™ 1176
and in vitro Skyscan 1272. The PCI lab also
features four optical molecular imaging systems for fluorescence,
luminescence, planar x-ray and planar radio-isotopic imaging
experiments, with two in vivo Xtreme™ optical systems and
two MS FX PRO™ optical imaging systems. The lab benefits
from a new electron paramagnetic resonance imaging (EPRI) system, and a minispec™
system for body composition analysis. A crucial component of employing
multi-modality imaging in most research environments is having a
comprehensive suite of imaging technologies that include reliable
co-registration devices. Bruker’s multimodal animal beds enable flexible
and versatile analyses of various animal models based on an easy and
productive workflow. On the Bruker Billerica campus, several MALDI mass
spectrometry imaging systems are accessible for in vitro small
molecule, lipids or peptide/protein spectroscopic imaging. Additionally,
a Bruker Albira II PET/SPECT/CT preclinical imaging system
is located nearby at Boston Children’s Hospital, with access to PET and
SPECT isotopes.
About Bruker Corporation
Bruker Corporation is a leading provider of high performance scientific
instruments and solutions for molecular and materials research, as well
as industrial, diagnostics and applied analysis. For more information,
please visit www.bruker.com.
For more information on Bruker’s preclinical imaging solutions, please
visit www.preclinicalimaging.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140129005227/en/
Copyright Business Wire 2014